ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1229517
CHEMBL1229517
Compound Name VEMURAFENIB
ChEMBL Synonyms ZELBORAF | VEMURAFENIB | RG 7204 | PLX-4032 | RO 5185426
Max Phase 4 (Approved)
Trade Names ZELBORAF
Molecular Formula C23H18ClF2N3O3S

Additional synonyms for CHEMBL1229517 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)c4ccc(Cl)cc4)c ...
Download SMILES
Standard InChI InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20( ...
Download InChI
Standard InChI Key GPXBXXGIAQBQNI-UHFFFAOYSA-N

Sources

  • AstraZeneca Deposited Data
  • BindingDB Database
  • British National Formulary
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1229517

Molecule Features

CHEMBL1229517 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:N First In Class:N Chirality:Achiral Molecule Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Serine/threonine-protein kinase B-raf inhibitor Serine/threonine-protein kinase B-raf FDA

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Leukemia, Myeloid, AcuteD015470EFO:0000222acute myeloid leukemia2ClinicalTrials
MelanomaD008545EFO:0000389cutaneous melanoma4ClinicalTrials
NeoplasmsD009369EFO:0000311cancer4ClinicalTrials
Thyroid NeoplasmsD013964EFO:0002892thyroid carcinoma2ClinicalTrials
LymphomaD008223EFO:0000574lymphoma1ClinicalTrials
Carcinoma, Non-Small-Cell LungD002289EFO:0003060non-small cell lung carcinoma2ClinicalTrials
GliomaD005910EFO:0000326central nervous system cancer0ClinicalTrials
CraniopharyngiomaD003397EFO:1000209Craniopharyngioma2ClinicalTrials
Leukemia, Hairy CellD007943EFO:1000956hairy cell leukemia2ClinicalTrials
MelanomaD008545EFO:0002617metastatic melanoma4ClinicalTrials
DailyMed
Multiple MyelomaD009101EFO:0001378multiple myeloma2ClinicalTrials
NeoplasmsD009369EFO:0000616neoplasm4ATC
ClinicalTrials
MelanomaD008545EFO:0000756melanoma4ClinicalTrials
DailyMed
Colorectal NeoplasmsD015179EFO:1001951colorectal carcinoma2ClinicalTrials

Clinical Data

ClinicalTrials.gov VEMURAFENIB
The Cochrane Collaboration VEMURAFENIB

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL1229517. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL1169596 Serine/threonine-protein kinase A-Raf Homo sapiens 1.000
CHEMBL5145 Serine/threonine-protein kinase B-raf Homo sapiens 1.000
CHEMBL1906 Serine/threonine-protein kinase RAF Homo sapiens 1.000
CHEMBL2343 Serine/threonine-protein kinase Sgk1 Homo sapiens 0.996
CHEMBL4411 Prostaglandin E synthase 2 Homo sapiens 0.941
CHEMBL4600 Serine/threonine-protein kinase PAK 1 Homo sapiens 0.641



10uM


ChEMBL_ID Target Name Organism Score
CHEMBL1169596 Serine/threonine-protein kinase A-Raf Homo sapiens 1.000
CHEMBL1906 Serine/threonine-protein kinase RAF Homo sapiens 1.000
CHEMBL5145 Serine/threonine-protein kinase B-raf Homo sapiens 1.000
CHEMBL5464 Receptor-interacting serine/threonine-protein kinase 1 Homo sapiens 1.000
CHEMBL2343 Serine/threonine-protein kinase Sgk1 Homo sapiens 1.000
CHEMBL4600 Serine/threonine-protein kinase PAK 1 Homo sapiens 1.000
CHEMBL3397 Cytochrome P450 2C9 Homo sapiens 0.990
CHEMBL4411 Prostaglandin E synthase 2 Homo sapiens 0.541
CHEMBL4202 Serine/threonine-protein kinase 2 Homo sapiens 0.214

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
489.9 489.0725 5.54 7 91.92 ACID


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
4 2 1 6 2 1


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
6.26 1.63 4.1 3.03 4 33 0.33

Structural Alerts

There are 2 structural alerts for CHEMBL1229517. To view alerts please click here.

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 - ANTINEOPLASTIC AGENTS
L01X - OTHER ANTINEOPLASTIC AGENTS
L01XE - Protein kinase inhibitors
L01XE15 - vemurafenib

ChemSpider ChemSpider:GPXBXXGIAQBQNI-UHFFFAOYSA-N
DailyMed vemurafenib
Wikipedia Vemurafenib

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1229517



BindingDB 50396483
ChEBI 63637
ChemicalBook CB22515128 CB02550000
DrugBank DB08881
DrugCentral 4185
eMolecules 32176418
EPA CompTox Dashboard DTXSID50238710
FDA SRS 207SMY3FQT
Guide to Pharmacology 5893
IBM Patent System 288B08A5D2C2CB36C8EA9CF3F220C6E7
LINCS LSM-1068
Mcule MCULE-7244406627
MolPort MolPort-009-200-481
Nikkaji J2.870.988I
PDBe 032
PharmGKB PA165946873
PubChem 42611257
PubChem: Drugs of the Future 123055406
PubChem: Thomson Pharma 99207986
Selleck PLX-4032
SureChEMBL SCHEMBL298931
ZINC ZINC000052509366

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/GPXBXXGIAQBQNI-UHFFFAOYSA-N spacer
spacer